At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,521 enrolled
Drug / intervention
Fesoterodine (Toviaz)drug
Likely dose
Fesoterodine (Toviaz) 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DRUG USE INVESTIGATION FOR TOVIAZ
In Brief
An observational study evaluating Fesoterodine (Toviaz) for Overactive Bladder (OAB). Completed, enrolled 2,521 participants.
Detailed Summary
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder (OAB)
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartOct 2013
Primary CompletionMay 2016
TodayJul 2026
First PostedSep 6, 2013
Enrollment StartOct 1, 2013
Primary CompletionMay 19, 2016
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 12.8 years ago
Interventions
Fesoterodine (Toviaz)drug
Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.